Guidelines for antihypertensive therapy: Problems with a strategy based on absolute cardiovascular risk

Journal of Hypertension

Volumn 14, Issue 6, 1996, Pages 683-689

  Simpson, F Olaf ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Absolute cardiovascular risk; Antihypertensive treatment; Guidelines; Marginal cardiovascular risk

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; NEW ZEALAND; OBESITY; PATIENT SELECTION; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; SMOKING;

EID: 0029995523     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199606000-00002     Document Type: Review

References (44)

1. Alderman MH, Cushman WC, Hill MN, Krakoff LR: International roundtable discussion of national guidelines for the detection, evaluation, and treatment of hypertension. Am J Hypertens 1993, 6:974-981.
2. Swales JD: Hypertension octet. Pharmacological treatment of hypertension. Lancet 1994, 344:380-385.
3. Swales JD: Sticking to guidelines can be expensive. BMJ 1994, 308:855.
4. National Advisory Committee on Core Health and Disability Support Services: The Management of Raised Blood Pressure in New Zealand. Wellington: Ministry of Health; 1992.
5. Jackson R, Barham P, Bills J, Birch T, McLennan L, McMahon S, et al.: Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993, 307:107-110.
6. Anderson KM, Wilson PWF, Odell PM, Kannel WB: An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83:356-362.
7. Wolf PA, d'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham study. Stroke 1991, 22:312-318.
8. MacMahon SW, Cutler JA, Furberg CD, Payne GH: The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Progr Cardiovasc Dis 1986, 29 (suppl 1):99-118.
9. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al.: Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990, 335:827-838.
10. Core Services Committee: Guidelines for the Management of Mildly Raised Blood Pressure in New Zealand. Wellington: Ministry of Health; 1995.
11. Kaplan NM: Clinical aspects of hypertension. Hypertens Res 1994, 17:205-213.
12. Watt GCM: Prevention of high blood pressure and its complications: strategic issues in a local context. J Hypertens 1995, 13:377-383.
13. Menard J, Chatellier G: Mild hypertension: the mysterious viability of a faulty concept. J Hypertens 1995, 13:1071-1077.
14. Alderman MH: Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993, 119:329-335.
15. Arroll B, Jenkins S, North D, Kearns R: Management of hypertension and the core services guidelines: results from interviews with 100 Auckland general practitioners. N Z Med J 1995, 108:55-57.
16. Stason WB, Weinstein MC: Allocation of resources to manage hypertension. N Engl J Med 1977, 296:732-739.
17. Beaglehole R, Bonita R, Jackson R, Stewart A: Prevention and control of hypertension in New Zealand. N Z Med J 1988, 101:480-483.
18. Kannel WB: Role of blood pressure in cardiovascular disease: the Framingham study. Angiology 1975, 26:1-14.
19. Amery A, Birkenhäger W, Brixko R, Bulpitt C, Clement D, Deruyttere M, et al.: Efficacy of anti-hypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet 1986, II:589-592.
20. Rajala S, Haavisto M, Heikinheimo R, Mattila K: Blood pressure and mortality in the very old [letter]. Lancet 1983, II:520-521.
21. Coope J, Warrender TS, McPherson K: The prognostic significance of hypertension in the elderly. J Hum Hypertens 1988, 2:79-88.
22. Wilson PWF, Kannel WB: Hypertension, other risk factors, and the risk of cardiovascular disease. In Hypertension: Pathophysiology, Diagnosis and Management. Second edition. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:99-114.
23. Barrett-Connor E, Khaw K-T: Is hypertension more benign when associated with obesity? Circulation 1985, 72:53-60.
24. Goldbourt U, Holtzman E, Cohen-Mandelzweig L, Neufeld HN: Enhanced risk of coronary heart disease in lean hypertensive men. Hypertension 1987, 10:22-28.
25. Menotti A, Giampaoli S, Pasquali M, Seccareccia F, Stuart K: Prognosis of lean and fat hypertensives. Cardiology 1988, 75:448-457.
26. Stamler R, Ford CE, Stamler J: Why do lean hypertensives have higher mortality rates than other hypertensives? Hypertension 1991, 17:553-564.
27. Tuomilehto J: Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on high blood pressure in the elderly. Am J Med 1991, 90 (suppl 3A):34S-41S.
28. Cruickshank JM: Coronary flow reserve and the J-curve relation between diastolic blood pressure and myocardial infarction. BMJ 1988, 297:1227-1230.
29. Lindblad U, Rȧstam L, Rydén L, Ranstam J, Isacsson S-O, Berglund G: Control of blood pressure and risk of first acute myocardial infarction: Skaraborg hypertension project. BMJ 1994, 308:681-686.
30. Prichard BNC, Cruickshank JM: Beta blockade in hypertension: past, present and future. In Hypertension: Pathophysiology, Diagnosis and Management. Second edition. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2827-2859.
31. Report by the Management Committee: The Australian therapeutic trial in mild hypertension. Lancet 1980, I:1261-1267.
32. Miall WE, Greenberg G: Mild Hypertension: Is There Pressure to Treat? Cambridge, UK: Cambridge University Press; 1987.
33. Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM: The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure responses of the study population. Progr Cardiovasc Dis 1986, 29 (suppl 1):11-28.
34. Simpson FO: No evidence that treatment of hypertension does not explain much of the decline in mortality from stroke in New Zealand. N Z Med J 1987, 100:452-453.
35. Simpson FO: Fallacies in the interpretation of the large-scale trials of treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1990, 16 (suppl 7):S92-S95.
36. Wilcox RG, Mitchell JRA, Hampton JR: Treatment of high blood pressure: should clinical practice be based on results of clinical trials? BMJ 1986, 293:433-437.
37. Hoes AW, Grobbee DE, Lubsen J: Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995, 13:805-811.
38. Peart WS, Meade TW: Mild hypertension: MRC working party report [letter]. BMJ 1988, 297:739.
39. Hampton JR: Mild hypertension: to treat or not to treat? Nephron 1986, 47 (suppl 1):57-61.
40. Lever AF, Ramsay LE: Treatment of hypertension in the elderly. J Hypertens 1995, 13:571-579.
41. Millar JA, Lever AF: Adjustment of the apparent benefits of treatment on stroke risk in the MRC mild hypertension trial using data from the placebo-treated group. J Hum Hypertens 1995, 9:409-412.
42. Bonita R, Beaglehole R: The decline in stroke mortality: the limited role of antihypertensive therapy. N Z Med J 1987, 100:454-456.
43. Bonita R, Beaglehole R: Does treatment of hypertension explain the decline in mortality from stroke? BMJ 1986, 292:191-192.
44. Dannenberg AL, Kannel WB: Remission of hypertension. The 'natural' history of blood pressure treatment in the Framingham study. JAMA 1987, 257:1477-1483.